Hyacinthe Johnson‐Ansah
- Hematology top 5%
- Chronic Myeloid Leukemia Treatments 13
- Acute Myeloid Leukemia Research 2
- Erythropoietin and Anemia Treatment 1
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 9
- Myeloproliferative Neoplasms: Diagnosis and Treatment 2
- Rheumatology top 10%
- Eosinophilic Disorders and Syndromes 6
-
- HER2/EGFR in Cancer Research 2
-
- Acute Lymphoblastic Leukemia research 4
- Co-authors
- Laurence LegrosDelphine RéaGabriel ÉtienneMartine GardembasFrançois‐Xavier MahonFrançois GuilhotMartine Escoffre‐BarbeValérie Coiteux
- Cited by
- HematologyGeneticsRheumatology
- Partner nations
- FranceTürkiyeUnited Kingdom
In The Last Decade
Hyacinthe Johnson‐Ansah
18 papers receiving 403 citations
Peers
Comparison fields: 5 of 47
- Hematology 353
- Genetics 293
- Rheumatology 161
- Oncology 90
- Pathology and Forensic Medicine 42
Countries citing papers authored by Hyacinthe Johnson‐Ansah
This map shows the geographic impact of Hyacinthe Johnson‐Ansah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyacinthe Johnson‐Ansah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyacinthe Johnson‐Ansah more than expected).
Fields of papers citing papers by Hyacinthe Johnson‐Ansah
This network shows the impact of papers produced by Hyacinthe Johnson‐Ansah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyacinthe Johnson‐Ansah. The network helps show where Hyacinthe Johnson‐Ansah may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hyacinthe Johnson‐Ansah, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2023 | 1 | |
| 3 | 2022 | 3 | |
| 4 | 2019 | 9 | |
| 5 | 2018 | 20 | |
| 6 | 2018 | 48 | |
| 7 | 2017 | 17 | |
| 8 | 2016 | 6 | |
| 9 | 2016 | 11 | |
| 10 | 2016 | 230 | |
| 11 | 2016 | 5 | |
| 12 | 2014 | 13 | |
| 13 | 2013 | 1 | |
| 14 | 2013 | 10 | |
| 15 | 2013 | 3 | |
| 16 | 2012 | 30 | |
| 17 | 2012 | 5 | |
| 18 | 2011 | 1 |
About Hyacinthe Johnson‐Ansah
Hyacinthe Johnson‐Ansah is a scholar working on Hematology, Genetics and Rheumatology, having authored 18 papers that have together received 414 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (13 papers), Chronic Lymphocytic Leukemia Research (9 papers), Eosinophilic Disorders and Syndromes (6 papers), Acute Lymphoblastic Leukemia research (4 papers), Acute Myeloid Leukemia Research (2 papers), HER2/EGFR in Cancer Research (2 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers) and Erythropoietin and Anemia Treatment (1 paper). The work is most often cited by research in Hematology (353 citations), Genetics (293 citations) and Rheumatology (161 citations). Hyacinthe Johnson‐Ansah has collaborated with scholars based in France, Türkiye and United Kingdom. Frequent co-authors include Laurence Legros, Delphine Réa, Gabriel Étienne, Martine Gardembas, François‐Xavier Mahon, François Guilhot, Martine Escoffre‐Barbe, Valérie Coiteux, Aude Charbonnier and Agnès Guerci‐Bresler. Their work appears in journals such as Blood, PLoS ONE and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.